DNA修复
同源重组
DNA损伤
基因组不稳定性
恶性肿瘤
癌症研究
医学
DNA错配修复
DNA
生物信息学
卵巢癌
癌症
生物
DNA损伤修复
同源染色体
聚ADP核糖聚合酶
后天抵抗
合成致死
作者
Isabel Miras,Inmaculada Vázquez-Gutierrez,Purificación Estévez-García,Sandra Muñoz-Galván
标识
DOI:10.1016/j.biopha.2025.118719
摘要
Ovarian cancer (OC) is the gynecological malignancy with the highest mortality, largely due to frequent resistance to conventional therapies. OC is characterized by high rates of genomic instability, often caused by DNA repair defects, and is commonly treated with platinum-based compounds and other genotoxic agents. Indeed, alterations in the DNA damage response (DDR), which are prevalent in many cancers, are particularly relevant in OC. Notably, homologous recombination deficiency is frequently observed, providing a rationale for strategies to enhance treatment efficacy by exploiting DNA repair defects. In this review, we examine the consequences of dysregulation and defects in the major DNA repair pathways in OC, with emphasis on their impact on therapy resistance, patient survival and OC risk. We also discuss current and emerging DDR-targeted therapies and highlight future directions for research aimed at improving clinical outcomes in OC.
科研通智能强力驱动
Strongly Powered by AbleSci AI